Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

NCT03163381 | Unknown Phase 2

• 1 other identifier: AHEAD-HNP007
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Apatinib second line treatment for Advanced osteosarcoma and soft tissue sarcomas ,openting ,single center, one-armed clinical study.

Conditions

Osteosarcoma, Advanced

Keywords

first-line treatment failure; one measurable lesion

Outcome Measures

Primary Outcomes (1)

• progress free survival

  time from study drug treatment to tumor progress

  6 months

Secondary Outcomes (1)

• overall survival

  up to 24 months

Study Arms (1)

Apatinib

EXPERIMENTAL

Apatinib 500mg/d from day 1 to day 28, repeated every 28 days until progressive Disease(PD) .

Drug: Apatinib

Interventions

Apatinib DRUG

Apatinib 500mg,po,qd,medicine to disease progression.

Apatinib

Eligibility Criteria

• Age: 18 Years - 70 Years
• Gender Eligibility Details: 18 to 70 years (including 18 and 70 ).
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject joined the study of his or her own free will , signed informed consent;
• Subject that diagnosed with advanced osteosarcoma by pathology and first-line treatment failure, at least have one measurable lesion ; Or confirmed by the pathology of advanced soft tissue sarcomas, at least have one measurable lesion,main include Synovial sarcoma、 Leiomyosarcoma、Alveolar soft part sarcoma、Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma、Adipocytic Tumors、 Fibrosarcoma、Clear cell sarcoma、Epithelioid sarcoma、Malignant peripheral nerve sheath tumor、Undifferentiatedsarcoma、 Rhabdomyosarcoma、chondrosarcoma、Osteosarcoma、Dermato- fibrosarcoma protuberans、GIST、Primitiveneuroectodermal tumor、Inflammatory myofibroblastic tumor、Malignant mesothelioma； 3）Within the past 6 months, Subject using at least one chemotherapy regimens (including anthracycline-based) failured (except gland alveolar soft tissue sarcoma); 4）18 to 70 years (including 18 and 70 ), men and women there is no limited. 5）ECOG PS score: 0 \~ 1; 6）Estimated survival period more than 3 months; 7）Main organs function within 7 days before the treatment, meet the following criteria:
• Blood routine examination standard( without blood transfusion condition in 14 days) :HB≥90g/L;②ANC≥1.5×109/L;③PLT≥80×109/L
• Blood biochemical examination must meet the following criteria:
• ① TBIL≤1.5ULN ；②ALT and AST≤2.5ULN，if With hepatic metastatic carcinoma，ALT and AST≤5ULN；③Cr≤1.5ULN或CCr≥60ml/min；
• Doppler ultrasound assessment: LVEF normal or low limit (50%).

You may not qualify if:

• \- 1）Subject with hypertension, and after antihypertensive drug therapy can't to the normal range (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg), Ⅱ or higher level of coronary heart disease, arrhythmia (include QTc prolonging, male \> 450 ms, female \> 470 ms) and cardiac insufficiency; 2）Subject used targeted therapy of vascular endothelial growth inhibitor drug previous, include Sunitinib, Sorafenib ,bevacizumab, imatinib and so on.
• ）With other malignant tumor before or at the same time, but except the cured skin basal cell carcinoma and carcinoma in situ of cervix.
• ）Subject accepted anticancer therapy before with NCI CTCAE classification \> 1 grade toxicity reaction.
• ）Has multi-factors that effect of oral drug absorption(, such as unable to swallow, nausea or vomiting, chronic diarrhea and intestinal obstruction, etc.); 6）Special note: subject with gastrointestinal bleeding risk can't enrolled the study, include: (1) there are active peptic ulcer lesions, and defecate occult blood (+ +);(2)Subject with medical history include Melena、hematemesis in three months;(3) Subject must be of gastroscopy with defecate occult blood, clear whether deposit organic gastrointestinal tract diseases; 7）Subject with coagulant function abnormality (INR \> 1.5 x ULN, APTT \> 1.5 x ULN), bleeding tendency; 8）Didn't heal wounds for a long time or fracture. 9）Subject with active bleeding or within 30 days after Major surgery. 10）Intracranial metastasis; 11）Pregnant or lactating women; 12）cell toxic drug therapy, radiation therapy 3 weeks after treatment; Once took two or more targeted drugs, or once took other targeted drugs 3 months before enrollment.
• ）Suffered from other malignant tumor for the past three years. 14）Investigator considered that there may be exist any situation that can damage subject or result in subject can't meet or carry out Investigator requests.
• ）huge transfer/recurrent lesions(tumor size greater than 5 cm). 16）malignant pleuraleffusion or peritoneal effusion, caused NCI CTCAE grading more than 2 levels of breathing difficulties; Description: oversized tumor load often indicates poor blood supply, lead to drug unable to effectively into the tumor, in order to accurately assess the treatment effects apatinib to the soft tissue sarcomas, Our study do not accept with huge transfer recurrent focal (tumor diameter greater than 5 cm) of the patients into groups temporarily .
• ）Allergy to any ingredient about apatinibshould be ruled out; 18）Subject with severe liver and renal failure (level 4) should be ruled out; 19）Subject has a history of psychiatric drugs abuse and can't quit or have a mental disorder; 20）According to the investigator's judgment, subject who has concomitant diseases that serious to endanger the safety or impact subject to complete the study.

Sponsors & Collaborators

• Henan Cancer Hospital: lead
• Jiangsu HengRui Medicine Co., Ltd.: collaborator

Study Sites (1)

Henan cancer hospital

Zhengzhou, Henan, 450000, China

RECRUITING

Related Publications (1)

• Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14.

  PMID: 31401903 DERIVED

MeSH Terms

Conditions

Osteosarcoma

Interventions

apatinib

Condition Hierarchy (Ancestors)

Neoplasms, Bone Tissue; Neoplasms, Connective Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Sarcoma

Central Study Contacts

Weitao Yao

CONTACT

13298189535; ywtwhm@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Deputy Director

Study Record Dates

• First Submitted: May 18, 2017
• First Posted: May 23, 2017
• Study Start: April 11, 2017
• Primary Completion: October 11, 2017
• Study Completion: April 11, 2019
• Last Updated: May 23, 2017

Record last verified: 2017-05

Locations

CN (1)